BioWorld

Jan. 6, 2004

View Archived Issues

Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise

The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today) Read More

Corixa Gets $11.6M Grant From Government For TLR4 Agonists

Read More

Approved Rheumatoid Arthritis Drug Trimmed Patients' Dosage In Trials Conducted Nationwide

Read More

Dynogen Teams Up With J&J Unit For Overactive Bladder Treatment

Read More

New Jersey Signs Legislation Allowing Stem Cell Research

Read More

Other News To Note

Read More